VX 765 - CAS# 273404-37-8 282 InChi: InChI=1S/C31H31N3O5/c1-19-14-24(32-21(3)35)15-20(2)29(19)39-18-23-16-22(11-12-28(23)37-4)30-33-27-10-6-5-9-26(27)31(36)34(30)17-25-8-7-13-38-25/h5-16

InChi: InChI=1S/C31H31N3O5/c1-19-14-24(32-21(3)35)15-20(2)29(19)39-18-23-16-22(11-12-28(23)37-4)30-33-27-10-6-5-9-26(27)31(36)34(30)17-25-8-7-13-38-25/h5-16

PubMed Central PMCID: PMC2731875

2007 Feb 1

52(15):4683-93

VX 765 - CAS# 273404-37-8 282 InChi: InChI=1S/C31H31N3O5/c1-19-14-24(32-21(3)35)15-20(2)29(19)39-18-23-16-22(11-12-28(23)37-4)30-33-27-10-6-5-9-26(27)31(36)34(30)17-25-8-7-13-38-25/h5-16VX 765, CAS No. 273404 37 8, is designed to inhibit Caspase, which is an enzyme that controls the generation of two cytokines, IL 1b and IL 18. VX 765 has been shown to inhibit acute seizures in preclinical models. In addition, VX 765 has shown activity in preclinical models of chronic epilepsy. VX 765 had been dosed in over 100 patients in phase I and phase IIa clinical trials relating to other diseases, including a 28 day phase IIa clinical trial in